Navigation Links
Dr Steven Gillis to Join Shire Board of Directors
Date:9/4/2012

DUBLIN, Ireland, September 4, 2012 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Dr. Steven Gillis, Ph.D. will join the Board of Directors on October 1, 2012.  On joining the Board, Dr. Gillis will become a member of the Company's Science & Technology Committee and Remuneration Committee.

Dr. Gillis is currently a Managing Director at ARCH Venture Partners, a provider of venture capital for technology firms, where he is focused on the evaluation of new life science technologies and the development and growth of ARCH's biotechnology portfolio companies.  Prior to this, Dr. Gillis was a founder and director of Corixa Corporation, acquired by GlaxoSmithKline in 2005. Prior to starting Corixa, Dr. Gillis was a founder and director of Immunex Corporation.

An immunologist by training, Dr. Gillis has authored more than 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20) and the novel vaccine adjuvant, MPL.

He received his B.A. from Williams College in 1975 and his Ph.D. from Dartmouth College in 1978.

Dr. Gillis is a Non-Executive Director of Genesis Research and Development Corporation Limited., a New Zealand and Australian Stock Exchange-listed biotechnology company. He was a Non- Executive Director and then Executive Chairman and Acting President of Trubion Pharmaceuticals Inc., until its sale in 2010.

Shire Chairman, Matt Emmens, comments:

"Steven's pioneering and entrepreneurial approach paired with a deep technical and scientific knowledge will complement the existing skills and outlook of the Shire Board. I look forward to him joining in the autumn." 

Dr. Steven Gillis adds:

"Shire has a clear and ambitious patient-focused vision for the future and I look forward to the opportunity to help them achieve it."

There is no further information that is required to be disclosed under 9.6.13R of the UK Listing Rules.

Notes to editors

Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients' needs, we develop and provide healthcare in the areas of:

  • Behavioral Health and Gastro Intestinal conditions
  • Rare Diseases
  • Regenerative Medicine

as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value for patients, physicians, policymakers, payors and our shareholders.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine products, as well as the ability to secure new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.


For further information please contact:

Investor Relations
Eric Rojas
erojas@shire.com
+1-781-482-0999

Sarah Elton-Farr
seltonfarr@shire.com 
+44-1256-894157


Media
Jessica Mann (Corporate)      
jmann@shire.com      
+44-1256-894-280


'/>"/>
SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
2. Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
3. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
4. Shire Announces that the US Food and Drug Administration has Responded to its Citizen Petition for Adderall XR and has Approved One Abbreviated New Drug Application for Generic Adderall XR
5. Shire Second Quarter Product Sales Up 16%
6. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
7. Angeion Selects Hendrik Struik for Board of Directors
8. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
9. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
10. Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering
11. Young Innovations, Inc. Board Of Directors Declares Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Jan. 18, 2017  Kratom leaves, from a ... are often used to prepare tea-like beverages and ... million Americans annually to increase alertness, enhance well-being ... for minor aches and pains. PinneyAssociates, review of ... to assist FDA and DEA in determining the ...
(Date:1/18/2017)... SAN DIEGO , Jan. 18, 2017 /PRNewswire/ ... and innovative products to treat a variety of ... its lead compound DMT210, in a Phase 2 ... specifically developed to downregulate the proinflammatory cytokines in ... seen in acne rosacea. This ...
(Date:1/18/2017)... , Suiza, 18 de enero de 2017 /PRNewswire/ ... líderes lanzaron Access Accelerated, una iniciativa global para avanzar ... (NCD) y atención en países de renta baja y ... han alcanzado un punto de crisis, particularmente en países ... el 80 por ciento de las muertes relacionadas con ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... 2017 , ... Anesthesia Progress – Everyone wants less pain during ... option for each patient. Dentists have several general anesthesia alternatives and finding the right ... the Tokyo Dental College in Tokyo, Japan wanted to find out which anesthetic was ...
(Date:1/17/2017)... ... , ... For breast cancer clinicians and researchers who were unable to attend ... intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual ... on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... SunView Software’s ... Award for Innovation of the Year. , Each year, Pink Elephant recognizes ... an innovative approach to address a specific business problem or opportunity. The award highlights ...
(Date:1/17/2017)... Chapel, Florida (PRWEB) , ... January 17, 2017 ... ... Connected City, a new 21st century approach to infusing high speed technology into ... an area exclusively dedicated to the advancement of healthcare and wellness in a ...
(Date:1/17/2017)... ... January 17, 2017 , ... Medic-CE ... EMS and firefighting professionals, has released four new continuing education courses as part ... taught live in an online classroom and meet the requirements of the National ...
Breaking Medicine News(10 mins):